Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis

Sheilabi Seeburun, Mohamad Cherry

Blood (2025) 146 (Supplement 1): 7669.

https://doi.org/10.1182/blood-2025-7669

Published: 2025

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Inferior vena cava agenesis presenting as iliofemoral deep vein thrombosis in a 49-year-old male

Eduardo Leon, Garrett Cherry, Karen Romero, Anuradha Hooda, Elizabeth Valenzuela, Ana Trujillo

Blood (2025) 146 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2025-6664

Published: 2025

Journal Articles

Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era

Mahija Cheekati, Danielle Thor, John Rutledge, Mohamad Cherry

Blood (2025) 146 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2025-4462

Published: 2025

Journal Articles

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Alexander Hamil, Ibrahim Aldoss, Shannon Maude, Ashish Bajel, Armin Ghobadi, Rawan Faramand, Tom Leedom, Michael Rettig, Cherry Thomas, Ayman Kabakibi, Deepa Bhojwani

Blood (2025) 146 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2025-4163

Published: 2025

Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Blood (2024) 144 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2024-194525

Published: 2024

Journal Articles

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Blood (2024) 144 (Supplement 1): 7463.

https://doi.org/10.1182/blood-2024-194638

Published: 2024

Journal Articles

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2024-194857

Published: 2024

Journal Articles

Dose of Venetoclax in Combination with Hypomethylating Agents and Outcomes of Patients with Acute Myeloid Leukemia: A Retrospective Study

Farah Yassine, Firas Saad, Mahija Cheekati, John Rutledge, Brian Baksa, Mohamad Cherry

Blood (2024) 144 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2024-194499

Published: 2024

Journal Articles

Risk and Protective Factors for COVID-19 Infection Among Pregnant Women with Sickle Cell Trait

Kim Abbegail Tan Aldecoa, Camelia Arsene, Tiffany Chng, Garett Cherry, Nabila Chowdhury, Ryan Clark, Dana Deeb, Lisa Deptula, Grey Dietz, Ewomamobuho Eto, Victoria Golston, Landon Lawson, Chioma Mbionwu, Obiefuna Okponyia, Jennifer Orejuela, Thomaida Qipo, Sumit Raut, Geetha Krishnamoorthy, Judie Goodman

Blood (2023) 142 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2023-185167

Published: 2023

Journal Articles

Evaluating the Effectiveness of COVID-19 Vaccines in Adults with Sickle Cell Disease during the Omicron Period of COVID-19 Pandemic

Blood (2023) 142 (Supplement 1): 1149.

https://doi.org/10.1182/blood-2023-185320

Published: 2023

Journal Articles

A Fatal Case of Hemophagocytic Lymphohistiocytosis Triggered By Babesiosis

Mahija Cheekati, Matthew Knapp, Farah Yassine, Megha Chiruvella, Mohamad A. Cherry

Blood (2023) 142 (Supplement 1): 5387.

https://doi.org/10.1182/blood-2023-181759

Published: 2023

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

Anemia Outside the Box: Nonimmune Intramedullary Hemolytic Anemia Driven By Vitamin B12 Deficiency

Farah Yassine, Mostafa Naguib, Mahija Cheekati, Geoffrey Nasuti, Megha Chiruvella, Mohamad A. Cherry

Blood (2023) 142 (Supplement 1): 5198.

https://doi.org/10.1182/blood-2023-179699

Published: 2023

Journal Articles

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Megan Randall, Chen Zhang, Matthew Kroll, Kelsey Pandrangi, Gautham Prakash, Cherry Au, Ashley Dunton, Yanyu Zhang, Melissa L. Larson, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 12288–12289.

https://doi.org/10.1182/blood-2022-167402

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Yuliya Linhares, Fei Fei Liu, Cesar Freytes, Mohamad Cherry, Ling Shi, Weiqin Liao, Julia Braverman, Ricardo Espinola, Min Vedal, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10930–10931.

https://doi.org/10.1182/blood-2022-159645

Published: 2022

Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein

Blood (2022) 140 (Supplement 1): 3333–3335.

https://doi.org/10.1182/blood-2022-156564

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10416–10418.

https://doi.org/10.1182/blood-2022-159595

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Inferior vena cava agenesis presenting as iliofemoral deep vein thrombosis in a 49-year-old male

Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Dose of Venetoclax in Combination with Hypomethylating Agents and Outcomes of Patients with Acute Myeloid Leukemia: A Retrospective Study

Risk and Protective Factors for COVID-19 Infection Among Pregnant Women with Sickle Cell Trait

Evaluating the Effectiveness of COVID-19 Vaccines in Adults with Sickle Cell Disease during the Omicron Period of COVID-19 Pandemic

A Fatal Case of Hemophagocytic Lymphohistiocytosis Triggered By Babesiosis

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Anemia Outside the Box: Nonimmune Intramedullary Hemolytic Anemia Driven By Vitamin B12 Deficiency

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only